Bartolome Celli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10986934/publications.pdf

Version: 2024-02-01

100 papers	18,935 citations	36691 53 h-index	42259 96 g-index
103 all docs	103 docs citations	103 times ranked	13290 citing authors

#	Article	IF	Citations
1	ANTES: Un aÃ±o despuÃ©s en la EPOC. Archivos De Bronconeumologia, 2022, 58, 291-294.	0.4	1
2	The 7 Cardinal Sins of COPD in Spain. Archivos De Bronconeumologia, 2022, 58, 498-503.	0.4	0
3	Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASCS Trial. International Journal of COPD, 2022, Volume 17, 273-282.	0.9	0
4	[Translated article] The ANTES Program in COPD: First Year. Archivos De Bronconeumologia, 2022, 58, T291-T294.	0.4	0
5	Pharmacotherapy Impacts on COPD Mortality. Archivos De Bronconeumologia, 2021, 57, 5-6.	0.4	4
6	Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet, The, 2021, 397, 928-940.	6.3	176
7	Spirometry: A practical lifespan predictor of global health and chronic respiratory and non-respiratory diseases. European Journal of Internal Medicine, 2021, 89, 3-9.	1.0	19
8	Metformin: Experimental and Clinical Evidence for a Potential Role in Emphysema Treatment. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 651-666.	2.5	49
9	Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. European Respiratory Journal, 2021, 57, 2001339.	3.1	26
10	Time for a change: anticipating the diagnosis and treatment of COPD. European Respiratory Journal, 2020, 56, 2002104.	3.1	33
11	Machine Learning and Prediction of All-Cause Mortality in COPD. Chest, 2020, 158, 952-964.	0.4	62
12	Plasma metabolomics and clinical predictors of survival differences in COPD patients. Respiratory Research, 2019, 20, 219.	1.4	22
13	Long-Acting Î²-Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1641-1644.	2.5	4
14	Shorter telomeres in non-smoking patients with airflow limitation. Respiratory Medicine, 2018, 138, 123-128.	1.3	6
15	Comparison of the 2017 and 2015 Global Initiative for Chronic Obstructive Lung Disease Reports. Impact on Grouping and Outcomes. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 463-469.	2.5	63
16	Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. International Journal of COPD, 2018, Volume 13, 3971-3981.	0.9	56
17	Inhaled corticosteroids in COPD: friend or foe?. European Respiratory Journal, 2018, 52, 1801219.	3.1	166
18	The Challenge of Controlling the COPD Epidemic: Unmet Needs. American Journal of Medicine, 2018, 131, 1-6.	0.6	33

#	Article	IF	Citations
19	What does endotyping mean for treatment in chronic obstructive pulmonary disease?. Lancet, The, 2017, 390, 980-987.	6.3	78
20	Expert Statement on the Single-Agent Use of Inhaled Bronchodilator in the Treatment of Stable Mild-Moderate Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2017, 53, 574-582.	0.4	0
21	Documento de expertos del uso de broncodilatadores inhalados en monoterapia en el tratamiento de la EPOC estable leve-moderada. Archivos De Bronconeumologia, 2017, 53, 574-582.	0.4	2
22	Telomere shortening and accelerated aging in COPD: findings from the BODE cohort. Respiratory Research, 2017, 18, 59.	1.4	46
23	Natural history of COPD: gaps and opportunities. ERJ Open Research, 2017, 3, 00117-2017.	1.1	40
24	Impact and prevention of severe exacerbations of COPD: a review of the evidence. International Journal of COPD, 2017, Volume 12, 2891-2908.	0.9	162
25	The EASI model: A first integrative computational approximation to the natural history of COPD. PLoS ONE, 2017, 12, e0185502.	1.1	4
26	Agreement between a simple dyspnea-guided treatment algorithm for stable COPD and the GOLD guidelines: a pilot study. International Journal of COPD, 2016, 11, 1217.	0.9	11
27	Differences in Health-Related Quality of Life Between New Mexican Hispanic and Non-Hispanic White Smokers. Chest, 2016, 150, 869-876.	0.4	8
28	DNA methylation profiling in human lung tissue identifies genes associated with COPD. Epigenetics, 2016, 11, 730-739.	1.3	73
29	The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1483-1493.	2.5	83
30	Functional Capacity, Health Status, and Inflammatory Biomarker Profile in a Cohort of Patients With Chronic Obstructive Pulmonary Disease. Journal of Cardiopulmonary Rehabilitation and Prevention, 2015, 35, 348-355.	1.2	8
31	Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 549.	0.9	26
32	Identification of Five Chronic Obstructive Pulmonary Disease Subgroups with Different Prognoses in the ECLIPSE Cohort Using Cluster Analysis. Annals of the American Thoracic Society, 2015, 12, 303-312.	1.5	126
33	Clinical and prognostic heterogeneity of C and D GOLD groups. European Respiratory Journal, 2015, 46, 250-254.	3.1	11
34	Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2015, 373, 111-122.	13.9	974
35	Lung-Function Trajectories and Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2015, 373, 1574-1575.	13.9	23
36	Low plasma CC16 levels in smokers are associated with a higher risk for chronic bronchitis. European Respiratory Journal, 2015, 46, 1501-1503.	3.1	19

#	Article	IF	Citations
37	Genetic control of gene expression at novel and established chronic obstructive pulmonary disease loci. Human Molecular Genetics, 2015, 24, 1200-1210.	1.4	43
38	Effect of Tiotropium on Outcomes in Patients With COPD, Categorized Using the New GOLD Grading System: Results of the UPLIFTÂ® Randomized Controlled Trial. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2015, 2, 236-251.	0.5	3
39	Disease progression in young patients with COPD: rethinking the Fletcher and Peto model. European Respiratory Journal, 2014, 44, 324-331.	3.1	57
40	A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease. BMC Systems Biology, 2014, 8, S8.	3.0	24
41	Common Genetic Variants Associated with Resting Oxygenation in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2014, 51, 678-687.	1.4	19
42	Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax, 2014, 69, 718-723.	2.7	151
43	Acute bronchodilator responses decline progressively over 4Âyears in patients with moderate to very severe COPD. Respiratory Research, 2014, 15, 102.	1.4	13
44	Lessons from ECLIPSE: a review of COPD biomarkers. Thorax, 2014, 69, 666-672.	2.7	125
45	Should We View Chronic Obstructive Pulmonary Disease Differently after ECLIPSE?. A Clinical Perspective from the Study Team. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1022-1030.	2.5	130
46	Rapid Lung Function Decline in Smokers Is a Risk Factor for COPD and Is Attenuated by Angiotensin-Converting Enzyme Inhibitor Use. Chest, 2014, 145, 695-703.	0.4	60
47	Once-Daily Umeclidinium/Vilanterol 125/25 Î¼g Therapy in COPD. Chest, 2014, 145, 981-991.	0.4	142
48	Comorbidity Distribution, Clinical Expression and Survival in COPD Patients with Different Body Mass Index. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 1, 229-238.	0.5	38
49	Effects of Tiotropium on Exacerbations in Patients with COPD with Low or High Risk of Exacerbations: A Post-Hoc Analysis from the 4-Year UPLIFTÂ® Trial. Chronic Obstructive Pulmonary Diseases (Miami, Fla) Tj ETQq1 1 0.784314 rgBT /Ov	1.5	54
50	Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respiratory Medicine, 2013, 107, 1376-1384.	1.3	328
51	The COPD Biomarker Qualification Consortium (CBQC). COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 367-377.	0.7	67
52	Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. Respiratory Medicine, 2013, 107, 1904-1911.	1.3	18
53	The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respiratory Medicine,the, 2013, 1, 129-136.	5.2	224
54	Six-Minute-Walk Test in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 382-386.	2.5	257

#	Article	IF	Citations
55	Reply: Minimal or Maximal Clinically Important Difference: Using Death to Define MCID. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1392-1392.	2.5	5
56	Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. European Respiratory Journal, 2013, 42, 636-646.	3.1	164
57	Reply: To COTE or Not to COTE: Generalizability, Validity, and Other Issues. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 805-805.	2.5	2
58	Genome-Wide Association Analysis of Blood Biomarkers in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1238-1247.	2.5	117
59	Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease. Journal of the American Medical Directors Association, 2012, 13, 291-297.	1.2	193
60	A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Human Molecular Genetics, 2012, 21, 947-957.	1.4	216
61	Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 155-161.	2.5	946
62	Exacerbation frequency and course of COPD. International Journal of COPD, 2012, 7, 653.	0.9	138
63	Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype. PLoS ONE, 2012, 7, e37483.	1.1	633
64	Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine, 2011, 105, 580-587.	1.3	96
65	Premature discontinuation during the UPLIFT study. Respiratory Medicine, 2011, 105, 1523-1530.	1.3	20
66	Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials. International Journal of COPD, 2011, 6, 269.	0.9	6
67	Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology, 2011, 16, 825-835.	1.3	43
68	Bias due to withdrawal in longâ€term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal, 2011, 5, 44-49.	0.6	78
69	Risk of Nonlower Respiratory Serious Adverse Events Following COPD Exacerbations in the 4-year UPLIFTÂ® Trial. Lung, 2011, 189, 261-268.	1.4	64
70	Adverse health consequences in COPD patients with rapid decline in FEV1 - evidence from the UPLIFT trial. Respiratory Research, 2011, 12, 129.	1.4	25
71	Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respiratory Research, 2011, 12, 6.	1.4	76
72	Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 317-322.	2.5	157

#	Article	IF	Citations
73	Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. Thorax, 2011, 66, 489-495.	2.7	61
74	Addressing the Complexity of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1129-1137.	2.5	166
75	Changes in Forced Expiratory Volume in 1 Second over Time in COPD. New England Journal of Medicine, 2011, 365, 1184-1192.	13.9	811
76	Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respiratory Research, 2010, 11, 122.	1.4	952
77	Cardiovascular Safety of Tiotropium in Patients With COPD. Chest, 2010, 137, 20-30.	0.4	185
78	Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFTÂ® trial. Respiratory Medicine, 2010, 104, 1495-1504.	1.3	68
79	Cardiovascular events in patients with COPD: TORCH Study results. Thorax, 2010, 65, 719-725.	2.7	177
80	Prevalence and Progression of Osteoporosis in Patients With COPD. Chest, 2009, 136, 1456-1465.	0.4	240
81	Biologic Lung Volume Reduction in Advanced Upper Lobe Emphysema. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 791-798.	2.5	103
82	Mortality in the 4-Year Trial of Tiotropium (UPLIFT) in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 948-955.	2.5	252
83	Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respiratory Research, 2009, 10, 59.	1.4	287
84	Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet, The, 2009, 374, 1171-1178.	6.3	430
85	Does Pharmacotherapy Reduce the Rate of Decline of Lung Function in COPD?. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 171-172.	2.5	2
86	A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2008, 359, 1543-1554.	13.9	1,969
87	Venous Admixture in COPD: Pathophysiology and Therapeutic Approaches. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008, 5, 376-381.	0.7	24
88	Lung Volume Reduction in Patients with COPD: Physiological and Clinical Implications. Current Respiratory Medicine Reviews, 2008, 4, 312-320.	0.1	0
89	Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2007, 356, 775-789.	13.9	2,963
90	Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax, 2007, 62, 595-601.	2.7	170

#	Article	IF	Citations
91	American Thoracic Society/European Respiratory Society Statement on Pulmonary Rehabilitation. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1390-1413.	2.5	1,644
92	Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD. Chest, 2006, 130, 647-656.	0.4	205
93	Use of Proteomic Patterns of Serum Biomarkers in Patients with Chronic Obstructive Pulmonary Disease: Correlation with Clinical Parameters. Proceedings of the American Thoracic Society, 2006, 3, 465-466.	3.5	28
94	Future perspectives in COPD. Respiratory Medicine, 2005, 99, S41-S48.	1.3	17
95	Gene Expression Profiling of Human Lung Tissue from Smokers with Severe Emphysema. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 601-610.	1.4	159
96	Clinical Trial Design Considerations in Assessing Longâ€Term Functional Impacts of Tiotropium in COPD: The Uplift Trial. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2004, 1, 303-312.	0.7	152
97	Improvement in Resting Inspiratory Capacity and Hyperinflation With Tiotropium in COPD Patients With Increased Static Lung Volumes *. Chest, 2003, 124, 1743-1748.	0.4	278
98	Power of Outcome Measurements to Detect Clinically Significant Changes in Pulmonary Rehabilitation of Patients With COPD. Chest, 2002, 121, 1092-1098.	0.4	214
99	Symptom-Limited Stair Climbing as a Predictor of Postoperative Cardiopulmonary Complications After High-Risk Surgery. Chest, 2001, 120, 1147-1151.	0.4	174
100	Estimation of Ventilatory Reserve by Stair Climbing. Chest, 1993, 104, 1378-1383.	0.4	106